McAdam LLC Acquires 4,426 Shares of Bristol-Myers Squibb (NYSE:BMY)

McAdam LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 84.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,641 shares of the biopharmaceutical company’s stock after buying an additional 4,426 shares during the period. McAdam LLC’s holdings in Bristol-Myers Squibb were worth $545,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Round Rock Advisors LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth about $201,000. Sutton Place Investors LLC grew its position in shares of Bristol-Myers Squibb by 3.6% in the 4th quarter. Sutton Place Investors LLC now owns 7,916 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 273 shares during the last quarter. Greenleaf Trust raised its stake in shares of Bristol-Myers Squibb by 17.9% during the 4th quarter. Greenleaf Trust now owns 30,177 shares of the biopharmaceutical company’s stock worth $1,707,000 after acquiring an additional 4,576 shares in the last quarter. Spire Wealth Management lifted its position in Bristol-Myers Squibb by 4.3% during the fourth quarter. Spire Wealth Management now owns 18,338 shares of the biopharmaceutical company’s stock valued at $1,037,000 after acquiring an additional 760 shares during the last quarter. Finally, Journey Strategic Wealth LLC boosted its stake in Bristol-Myers Squibb by 10.0% in the fourth quarter. Journey Strategic Wealth LLC now owns 7,157 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 650 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.5 %

Shares of BMY opened at $58.86 on Monday. The stock’s 50-day moving average price is $57.60 and its 200-day moving average price is $53.27. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $119.38 billion, a price-to-earnings ratio of -16.40, a PEG ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same quarter last year, the company earned $2.00 EPS. The business’s revenue was up 8.4% on a year-over-year basis. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.21%. Bristol-Myers Squibb’s payout ratio is presently -69.08%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Citigroup boosted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their price target for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $56.60.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.